Frassoni F, Giordano D, Podestà M, Piaggio G, Benvenuto F, Pitto A, Figari O, Dejana A, Lerma E, Vassallo F, Sessarego M, Carella A
Dipartimento Ematologia, Ospedale San Martino, Genova, Italy.
Bone Marrow Transplant. 1996 May;17 Suppl 3:S59-62.
The study was devised to evaluate whether it was possible to collect Philadelphia-negative precursor cells in patients with chronic myeloid leukaemia. The approach was based on previous experience showing that complete remission (Ph-negative bone marrow cells) is rarely achieved after chemotherapy and is very short-lasting. We decided to explore whether it was possible to collect Ph-negative precursor cells in peripheral blood during the early phase of haemopoietic recovery. These data show that: the collection of Ph-negative precursor cells occurred in 12/16 (75%) patients mobilized within one year of diagnosis (group A) versus 12/33 (36%) in patients with a history of more than one year of disease (group B). Furthermore the numbers of Ph-negative precursor cells were significantly much higher at diagnosis. Ten patients mobilized at diagnosis were subsequently autografted with such Ph-negative precursor cells. Five of them remain Ph-negative from 4 to 12 months while the other five have percentages of Ph-positive cells in their marrow ranging from 20% to 70%. In this stage of the disease the procedure is safe and associated with a very good compliance. Occasional restoration of Ph-negative haemopoiesis could be observed up to 40 months after autograft, in patients of group B, but most of patients revert to Ph-positive haemopoiesis. in conclusion these data suggest that it is possible to restore Ph-negative haemopoiesis in 70% of patients mobilized at diagnosis. This percentage represent the highest one can obtain without allogeneic BMT, and this includes patients who never would have been cytogenetic responders to IFN-alpha. Whether and how long for Ph-negative status can be maintained is a matter for future observation and study.
本研究旨在评估慢性髓性白血病患者是否有可能采集到费城染色体阴性的前体细胞。该方法基于以往经验,即化疗后很少能实现完全缓解(费城染色体阴性骨髓细胞),且缓解持续时间很短。我们决定探索在造血恢复早期是否有可能从外周血中采集到费城染色体阴性的前体细胞。这些数据表明:在诊断后一年内动员的16例患者中有12例(75%)采集到了费城染色体阴性的前体细胞(A组),而病程超过一年的33例患者中有12例(36%)采集到了(B组)。此外,诊断时费城染色体阴性的前体细胞数量明显多得多。10例在诊断时动员的患者随后接受了此类费城染色体阴性前体细胞的自体移植。其中5例在4至12个月内仍保持费城染色体阴性,而另外5例骨髓中费城染色体阳性细胞的百分比在20%至70%之间。在疾病的这个阶段,该操作是安全的,且患者依从性很好。在B组患者中,自体移植后长达40个月偶尔可观察到费城染色体阴性造血的恢复,但大多数患者又恢复为费城染色体阳性造血。总之,这些数据表明,在诊断时动员的患者中,70%有可能恢复费城染色体阴性造血。这个百分比是在不进行异基因骨髓移植的情况下所能获得的最高百分比,这包括那些对α干扰素从未有过细胞遗传学反应的患者。费城染色体阴性状态能否维持以及能维持多久有待未来观察和研究。